JP2016516723A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516723A5 JP2016516723A5 JP2016503109A JP2016503109A JP2016516723A5 JP 2016516723 A5 JP2016516723 A5 JP 2016516723A5 JP 2016503109 A JP2016503109 A JP 2016503109A JP 2016503109 A JP2016503109 A JP 2016503109A JP 2016516723 A5 JP2016516723 A5 JP 2016516723A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 49
- 239000000427 antigen Substances 0.000 claims 47
- 102000036639 antigens Human genes 0.000 claims 47
- 108091007433 antigens Proteins 0.000 claims 47
- 229960005486 vaccine Drugs 0.000 claims 39
- 206010028980 Neoplasm Diseases 0.000 claims 28
- 201000011510 cancer Diseases 0.000 claims 28
- 241000701806 Human papillomavirus Species 0.000 claims 21
- 239000002773 nucleotide Substances 0.000 claims 14
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 241000711549 Hepacivirus C Species 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 230000002265 prevention Effects 0.000 claims 12
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 11
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 241000700721 Hepatitis B virus Species 0.000 claims 8
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 8
- 102000036673 PRAME Human genes 0.000 claims 8
- 108060006580 PRAME Proteins 0.000 claims 8
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 6
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 6
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 6
- 102000003425 Tyrosinase Human genes 0.000 claims 6
- 108060008724 Tyrosinase Proteins 0.000 claims 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 6
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims 4
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims 4
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims 4
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 4
- 241000701828 Human papillomavirus type 11 Species 0.000 claims 4
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 4
- 108010010995 MART-1 Antigen Proteins 0.000 claims 4
- 102100025077 Melanoma-associated antigen 4 Human genes 0.000 claims 4
- 101710142969 Somatoliberin Proteins 0.000 claims 4
- 108010051081 dopachrome isomerase Proteins 0.000 claims 4
- 239000013612 plasmid Substances 0.000 claims 4
- 210000001550 testis Anatomy 0.000 claims 4
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 101710132601 Capsid protein Proteins 0.000 claims 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 3
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims 3
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims 3
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 3
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 3
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 3
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 101001005720 Homo sapiens Melanoma-associated antigen 4 Proteins 0.000 claims 2
- 101710204291 Melanoma-associated antigen 4 Proteins 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000011165 anus cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 102000001327 Chemokine CCL5 Human genes 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 1
- 206010038707 Respiratory papilloma Diseases 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- 208000001307 recurrent respiratory papillomatosis Diseases 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361799952P | 2013-03-15 | 2013-03-15 | |
| US61/799,952 | 2013-03-15 | ||
| PCT/US2014/029479 WO2014144885A2 (en) | 2013-03-15 | 2014-03-14 | Cancer vaccines and methods of treatment using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019026468A Division JP7256024B2 (ja) | 2013-03-15 | 2019-02-18 | ガンワクチン及びそれを用いた治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516723A JP2016516723A (ja) | 2016-06-09 |
| JP2016516723A5 true JP2016516723A5 (enExample) | 2017-03-30 |
| JP6769865B2 JP6769865B2 (ja) | 2020-10-14 |
Family
ID=51538388
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503109A Active JP6769865B2 (ja) | 2013-03-15 | 2014-03-14 | ガンワクチン及びそれを用いた治療方法 |
| JP2019026468A Active JP7256024B2 (ja) | 2013-03-15 | 2019-02-18 | ガンワクチン及びそれを用いた治療方法 |
| JP2021038385A Pending JP2021100944A (ja) | 2013-03-15 | 2021-03-10 | ガンワクチン及びそれを用いた治療方法 |
| JP2022184046A Pending JP2023021127A (ja) | 2013-03-15 | 2022-11-17 | ガンワクチン及びそれを用いた治療方法 |
| JP2025102558A Pending JP2025129169A (ja) | 2013-03-15 | 2025-06-18 | ガンワクチン及びそれを用いた治療方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019026468A Active JP7256024B2 (ja) | 2013-03-15 | 2019-02-18 | ガンワクチン及びそれを用いた治療方法 |
| JP2021038385A Pending JP2021100944A (ja) | 2013-03-15 | 2021-03-10 | ガンワクチン及びそれを用いた治療方法 |
| JP2022184046A Pending JP2023021127A (ja) | 2013-03-15 | 2022-11-17 | ガンワクチン及びそれを用いた治療方法 |
| JP2025102558A Pending JP2025129169A (ja) | 2013-03-15 | 2025-06-18 | ガンワクチン及びそれを用いた治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11419925B2 (enExample) |
| EP (2) | EP2968607B1 (enExample) |
| JP (5) | JP6769865B2 (enExample) |
| KR (4) | KR20150130284A (enExample) |
| CN (2) | CN105025932B (enExample) |
| AU (5) | AU2014228405B2 (enExample) |
| BR (1) | BR112015022367B1 (enExample) |
| CA (1) | CA2898126A1 (enExample) |
| EA (2) | EA034110B1 (enExample) |
| MX (2) | MX369709B (enExample) |
| WO (1) | WO2014144885A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2565201B1 (en) | 2005-10-17 | 2014-11-26 | Sloan-Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
| EP3117836A1 (en) | 2006-04-10 | 2017-01-18 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and uses thereof |
| AU2013207669C1 (en) | 2012-01-13 | 2018-05-31 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| KR102877281B1 (ko) * | 2012-12-13 | 2025-10-28 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Ｗｔ１ 백신 |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| PT2945647T (pt) | 2013-01-15 | 2020-11-26 | Memorial Sloan Kettering Cancer Center | Péptidos imunogénicos wt-1 e métodos de uso dos mesmos |
| KR20150130284A (ko) * | 2013-03-15 | 2015-11-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 백신 및 이를 이용한 치료 방법 |
| EP4070818A3 (en) * | 2014-01-06 | 2023-01-11 | The Trustees of the University of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| ES3040431T3 (en) | 2014-03-12 | 2025-10-31 | Yeda Res & Dev | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| AU2015279738A1 (en) | 2014-06-25 | 2016-12-22 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
| KR20240132103A (ko) | 2015-01-29 | 2024-09-02 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 관문 억제제 및 백신 조합 및 면역요법을 위한 이들의 사용 |
| WO2016168361A1 (en) * | 2015-04-14 | 2016-10-20 | Polynoma, Llc | Polyvalent vaccines and combination therapy for the treatment of melanoma |
| WO2017060360A1 (en) * | 2015-10-06 | 2017-04-13 | Invectys | Polyepitope constructs for use in immunotherapy |
| US11684656B2 (en) * | 2015-11-04 | 2023-06-27 | Taipei Veterans General Hospital | Combination therapy for malignant diseases |
| CN116327902A (zh) * | 2015-11-20 | 2023-06-27 | 纪念斯隆凯特林癌症中心 | 用于治疗癌症的方法和组合物 |
| SG11201805621SA (en) | 2016-01-19 | 2018-08-30 | Pfizer | Cancer vaccines |
| US20190030023A1 (en) * | 2016-01-22 | 2019-01-31 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| AU2017214656B2 (en) | 2016-02-05 | 2022-08-25 | Inovio Pharmaceuticals, Inc. | Cancer vaccines and methods of treatment using the same |
| EP3439670A4 (en) | 2016-04-08 | 2019-11-27 | The Regents of the University of California | MODIFIED HYALURONIC ACID HYGELS AND PROTEINS FOR THE TEMPORARY RELEASE OF BIOLOGICAL ACTIVE SUBSTANCES |
| CA3026172A1 (en) | 2016-06-02 | 2017-12-07 | Ultimovacs As | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| WO2018056825A1 (en) | 2016-09-23 | 2018-03-29 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Manipulation of immune activity by modulation of expression |
| US11464841B2 (en) * | 2016-09-30 | 2022-10-11 | The Trustees Of The University Of Pennsylvania | TERT immunogenic compositions and methods of treatment using the same |
| US11666646B2 (en) | 2016-12-26 | 2023-06-06 | National University Corporation Kobe University | Cancer therapy utilizing combination of oral tumor vaccine and immunosuppression inhibitor |
| EP3579885A4 (en) * | 2017-02-07 | 2020-12-16 | Nantcell, Inc. | MAXIMIZING T CELL MEMORY, COMPOSITIONS AND RELATED METHODS |
| MY192920A (en) * | 2017-03-15 | 2022-09-15 | Cancer Res Malaysia | Immunogenic peptide composition |
| BR112020010499A2 (pt) | 2017-12-13 | 2020-11-24 | Inovio Pharmaceuticals, Inc. | vacinas de câncer de alvo de mesotelina e usos das mesmas |
| KR102756354B1 (ko) * | 2017-12-13 | 2025-01-21 | 이노비오 파마수티컬즈, 인크. | Prame를 표적으로 하는 암 백신 및 이의 용도 |
| FR3078536A1 (fr) * | 2018-03-05 | 2019-09-06 | Peptinov Sas | Composition vaccinale anti-pd-1 |
| TWI787500B (zh) | 2018-04-23 | 2022-12-21 | 美商南特細胞公司 | 新抗原表位疫苗及免疫刺激組合物及方法 |
| US11564980B2 (en) * | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
| MX2020012649A (es) * | 2018-05-25 | 2021-07-02 | The Wistar Inst | Neoantígenos especificos de tumor y métodos de uso de estos. |
| WO2020020444A1 (en) * | 2018-07-24 | 2020-01-30 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| WO2021051065A1 (en) * | 2019-09-12 | 2021-03-18 | Inovio Pharmaceuticals, Inc. | Tert, wt-1, pmsa immunogenic compositions and methods of treatment using the same |
| JP2023510112A (ja) * | 2019-12-19 | 2023-03-13 | ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー | アフリカ豚熱ウイルスに対するワクチン、およびそれを使用する方法 |
| EP4117662A4 (en) | 2020-03-10 | 2024-04-03 | X4 Pharmaceuticals, Inc. | METHODS OF TREATING NEUTROPENIA |
| PE20230349A1 (es) | 2020-05-14 | 2023-03-02 | Inovio Pharmaceuticals Inc | Vacunas para la papilomatosis respiratoria recurrente y metodos para usar estas |
| CN111647066B (zh) * | 2020-07-01 | 2020-12-18 | 维肽瀛(上海)生物技术有限公司 | Wt1多肽肿瘤抑制剂 |
| CN114113611B (zh) * | 2021-12-13 | 2023-07-14 | 郑州大学 | 一种用于肝癌诊断的生物标志物及检测试剂盒 |
| EP4463151A4 (en) * | 2022-01-19 | 2025-10-01 | Univ Northwestern | Agents Targeting Telomerase Reverse Transcriptase (TERT) to Treat Cancer and Sensitize Cancer Cells to Genotoxic Therapy |
| EP4489774A1 (en) * | 2022-03-08 | 2025-01-15 | ImmunityBio, Inc. | Intratumorally injected yeast vaccine |
| CN115845039A (zh) * | 2022-07-01 | 2023-03-28 | 可蓝赛生物医药(上海)有限公司 | 一种广谱多肽肿瘤疫苗组成 |
| EP4601687A1 (en) * | 2022-10-13 | 2025-08-20 | Inovio Pharmaceuticals, Inc. | Vaccines for recurrent respiratory papillomatosis and methods of using the same |
| CN118141903B (zh) * | 2024-03-11 | 2025-09-23 | 上海申锐联生物医药有限公司 | 一种治疗犬黑色素瘤的环状rna疫苗 |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| ZA858044B (en) | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
| US5643579A (en) | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US5223424A (en) | 1985-09-06 | 1993-06-29 | Prutech Research And Development | Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence |
| US4790987A (en) | 1985-11-15 | 1988-12-13 | Research Corporation | Viral glycoprotein subunit vaccine |
| US5310668A (en) | 1986-06-20 | 1994-05-10 | Merck & Co., Inc. | Varicella-zoster virus as a live recombinant vaccine |
| US5242829A (en) | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
| US5294441A (en) | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
| IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
| US5387744A (en) | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
| US5112749A (en) | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
| US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| JP3044062B2 (ja) | 1989-03-08 | 2000-05-22 | ヘルス・リサーチ・インク | 組換えポックスウイルス宿主選択系 |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
| AU645489B2 (en) | 1989-03-31 | 1994-01-20 | Washington University | Vaccines containing avirulent phoP-type microorganisms |
| ES2070997T3 (es) | 1989-12-04 | 1995-06-16 | Akzo Nobel Nv | Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos. |
| US5294548A (en) | 1990-04-02 | 1994-03-15 | American Biogenetic Sciences, Inc | Recombianant Hepatitis a virus |
| WO1991018088A1 (en) | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
| US5462734A (en) | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
| US5240703A (en) | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
| US5925729A (en) * | 1991-05-23 | 1999-07-20 | Ludwig Institute For Cancer Research | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
| US6034298A (en) | 1991-08-26 | 2000-03-07 | Prodigene, Inc. | Vaccines expressed in plants |
| US5955088A (en) | 1992-02-03 | 1999-09-21 | Cedars-Sinai Medical Center | Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins |
| AU4528493A (en) | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
| US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| PT681483E (pt) | 1993-01-26 | 2005-11-30 | Wyeth Corp | Composicoes e metodos para distribuicao de material genetico |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| NZ267838A (en) | 1993-06-07 | 1997-12-19 | Genentech Inc | Preparation of an hiv gp 120 subunit vaccine involving determining a neutralising epitope in the v2 and/or c4 domains |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US6156319A (en) | 1994-07-25 | 2000-12-05 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex vaccine |
| NL9401820A (nl) | 1994-11-02 | 1996-06-03 | Meyn Maschf | Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte. |
| US5843648A (en) * | 1995-01-10 | 1998-12-01 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5650309A (en) | 1995-05-16 | 1997-07-22 | The Regents Of The University Of California | Viral vectors |
| US5698202A (en) | 1995-06-05 | 1997-12-16 | The Wistar Institute Of Anatomy & Biology | Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier |
| US7501501B2 (en) | 1995-09-26 | 2009-03-10 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | MHC-Class II restricted melanoma antigens and their use in therapeutic methods |
| US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US6946133B1 (en) | 1996-03-20 | 2005-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Prostate specific antigen oligo-epitope peptide |
| WO1998017799A1 (en) | 1996-10-23 | 1998-04-30 | The Trustees Of The University Of Pennsylvania | Immunotherapy and improved vaccines |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| US6110161A (en) | 1997-04-03 | 2000-08-29 | Electrofect As | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
| CA2294793A1 (fr) | 1997-06-30 | 1999-01-14 | Rhone-Poulenc Rorer S.A. | Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede |
| US20030138808A1 (en) * | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
| JP2003505114A (ja) | 1998-07-13 | 2003-02-12 | ジェネトロニクス、インコーポレーテッド | パルス電場による皮膚および筋肉を標的とした遺伝子治療 |
| US6589529B1 (en) | 1998-10-30 | 2003-07-08 | Children's Hospital Medical Center | Rotavirus subunit vaccine |
| KR20010103788A (ko) * | 1999-03-03 | 2001-11-23 | 멕코나시 에블린 에이치. | 백신 및 유전자요법 조성물 및 이들의 제조 및 사용방법 |
| DE60142615D1 (de) * | 2000-04-28 | 2010-09-02 | Mannkind Corp | Epitop-synchronisierung in antigen präsentierenden zellen |
| US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
| WO2002068653A2 (en) | 2001-02-26 | 2002-09-06 | Imclone Systems Incorporated | Tri-hybrid melanoma antigen |
| US8771702B2 (en) | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
| JP4273293B2 (ja) | 2001-05-18 | 2009-06-03 | 大日本住友製薬株式会社 | Ｇｒｆ作用の阻害による新規抗自己免疫疾患剤、及びそのスクリーニング方法 |
| EP1260229A3 (en) | 2001-05-18 | 2002-12-11 | Sumitomo Pharmaceuticals Company, Limited | Anti-autoimmune composition comprising inhibitors of growth hormone-releasing factor activity |
| EP1270732A1 (en) | 2001-06-21 | 2003-01-02 | Schuler, Gerold | Improved transfection of eukaryontic cells with linear polynucleotides by electroporation |
| JP3543326B2 (ja) | 2001-08-30 | 2004-07-14 | ソニー株式会社 | 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム |
| CN101024842A (zh) | 2001-11-07 | 2007-08-29 | 曼康公司 | 编码靶相关抗原表位的表达载体及其设计方法 |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US20040106128A1 (en) * | 2002-06-27 | 2004-06-03 | Majumdar Anish Sen | Cancer vaccines containing xenogeneic epitopes of telomerase reverse transcriptase |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| US7906620B2 (en) * | 2002-08-16 | 2011-03-15 | Yeda Research And Development Co. Ltd. | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
| CN1720060B (zh) * | 2002-10-03 | 2011-12-14 | 惠氏控股公司 | 人乳头瘤病毒多肽和免疫原性组合物 |
| US20040175727A1 (en) | 2002-11-04 | 2004-09-09 | Advisys, Inc. | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
| US20040253606A1 (en) * | 2002-11-26 | 2004-12-16 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| CA2519953C (en) * | 2003-03-24 | 2016-01-05 | The Scripps Research Institute | Dna vaccine against tumor growth and methods of use thereof |
| DK2364769T3 (en) | 2003-05-30 | 2016-04-11 | Vgxi Inc | Apparatus and methods for biomaterialeproduktion |
| US20080171058A1 (en) | 2003-11-13 | 2008-07-17 | Polly Gregor | Compositions and Methods For Synergistic Induction of Antitumor Immunity |
| EP2301428B1 (en) * | 2003-12-09 | 2016-11-30 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
| GB0401876D0 (en) | 2004-01-28 | 2004-03-03 | Vereniging Het Nl Kanker I | New use for cancer antigen |
| DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| KR101710981B1 (ko) | 2006-07-28 | 2017-02-28 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 개선된 백신 및 이의 사용 방법 |
| AU2013203229C1 (en) * | 2006-07-28 | 2015-10-29 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
| WO2008085562A2 (en) | 2006-09-20 | 2008-07-17 | The Johns Hopkins University | Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies |
| US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| WO2008039974A2 (en) | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| EP2076531B1 (en) * | 2006-10-12 | 2011-11-23 | Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. | Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof |
| WO2008053573A1 (fr) | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Remède pour néoplasme malin |
| WO2008148010A1 (en) | 2007-05-23 | 2008-12-04 | Vgx Pharmaceuticals, Inc. | Composition comprising high concentration of biologically active molecules and processes for preparing the same |
| US8829174B2 (en) | 2008-10-29 | 2014-09-09 | The Trustees Of The University Of Pennsylvania | HCV vaccines and methods for using the same |
| CA2740598C (en) | 2008-11-17 | 2018-05-22 | Mathura P. Ramanathan | Antigens that elicit immune response against flavivirus and methods of using same |
| WO2010068680A1 (en) | 2008-12-10 | 2010-06-17 | Mount Sinai School Of Medicine Of New York University | Thelper cell type 17 lineage-specific adjuvants, compositions and methods |
| CA2653478A1 (en) | 2009-01-23 | 2010-07-23 | Gregg Martin | Automated wash system for industrial vehicles |
| JP2012529283A (ja) | 2009-06-09 | 2012-11-22 | ヴァクソン バイオテック | 共有ｈｌａ−ｂ＊０７０２エピトープの同定、最適化および免疫療法のための使用 |
| US20110070212A1 (en) * | 2009-08-14 | 2011-03-24 | Allergan, Inc. | Methods of Treating Cancer Using Glucagon-Like Hormone Retargeted Endopeptidases |
| WO2011073901A1 (en) | 2009-12-14 | 2011-06-23 | Koninklijke Philips Electronics N.V. | Novel tumor markers |
| WO2011097640A1 (en) | 2010-02-08 | 2011-08-11 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same |
| EP2558109A4 (en) | 2010-04-16 | 2014-09-24 | Bellicum Pharmaceuticals Inc | METHOD FOR TREATING HARD TUMORS |
| EP2582836B1 (en) | 2010-06-18 | 2018-03-07 | Taiho Pharmaceutical Co., Ltd. | Prpk-tprkb modulators and uses thereof |
| KR101939150B1 (ko) * | 2010-11-12 | 2019-01-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도 |
| WO2013019603A2 (en) * | 2011-07-29 | 2013-02-07 | Inovio Pharmaceuticals, Inc. | Linear expression cassettes and uses thereof |
| NZ701324A (en) * | 2012-05-04 | 2016-09-30 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| EP2932264B1 (en) | 2012-12-14 | 2019-01-30 | BioNTech RNA Pharmaceuticals GmbH | Novel mhc-independent tumor-associated antigens |
| KR20150130284A (ko) * | 2013-03-15 | 2015-11-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 백신 및 이를 이용한 치료 방법 |
-
2014
- 2014-03-14 KR KR1020157024377A patent/KR20150130284A/ko not_active Ceased
- 2014-03-14 US US14/775,047 patent/US11419925B2/en active Active
- 2014-03-14 JP JP2016503109A patent/JP6769865B2/ja active Active
- 2014-03-14 KR KR1020257036389A patent/KR20250162628A/ko active Pending
- 2014-03-14 CN CN201480011372.2A patent/CN105025932B/zh active Active
- 2014-03-14 CA CA2898126A patent/CA2898126A1/en active Pending
- 2014-03-14 EP EP14764579.0A patent/EP2968607B1/en active Active
- 2014-03-14 EA EA201591674A patent/EA034110B1/ru not_active IP Right Cessation
- 2014-03-14 WO PCT/US2014/029479 patent/WO2014144885A2/en not_active Ceased
- 2014-03-14 EA EA201992251A patent/EA201992251A1/ru unknown
- 2014-03-14 CN CN202111612889.5A patent/CN114225019A/zh active Pending
- 2014-03-14 KR KR1020217031786A patent/KR20210123426A/ko not_active Ceased
- 2014-03-14 KR KR1020237014283A patent/KR20230062674A/ko not_active Ceased
- 2014-03-14 MX MX2015011486A patent/MX369709B/es active IP Right Grant
- 2014-03-14 AU AU2014228405A patent/AU2014228405B2/en active Active
- 2014-03-14 BR BR112015022367-2A patent/BR112015022367B1/pt active IP Right Grant
- 2014-03-14 EP EP19187568.1A patent/EP3607974A1/en active Pending
-
2015
- 2015-09-02 MX MX2019013756A patent/MX2019013756A/es unknown
-
2017
- 2017-08-10 AU AU2017213514A patent/AU2017213514B2/en active Active
-
2019
- 2019-02-18 JP JP2019026468A patent/JP7256024B2/ja active Active
- 2019-11-08 AU AU2019261784A patent/AU2019261784A1/en not_active Abandoned
-
2021
- 2021-03-10 JP JP2021038385A patent/JP2021100944A/ja active Pending
-
2022
- 2022-01-04 AU AU2022200016A patent/AU2022200016B2/en active Active
- 2022-07-20 US US17/813,762 patent/US20230012022A1/en active Pending
- 2022-11-17 JP JP2022184046A patent/JP2023021127A/ja active Pending
-
2024
- 2024-05-13 AU AU2024203144A patent/AU2024203144A1/en active Pending
-
2025
- 2025-06-18 JP JP2025102558A patent/JP2025129169A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516723A5 (enExample) | ||
| JP2021100944A5 (enExample) | ||
| KR102395498B1 (ko) | Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용 | |
| Lo et al. | Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies | |
| JP2021100944A (ja) | ガンワクチン及びそれを用いた治療方法 | |
| CN104640565B (zh) | 乙型肝炎病毒核心蛋白和表面抗原蛋白以及包含其的疫苗 | |
| JP2019526580A5 (enExample) | ||
| KR20170106453A (ko) | 관문 억제제 및 백신 조합 및 면역요법을 위한 이들의 사용 | |
| Cordeiro et al. | Current research into novel therapeutic vaccines against cervical cancer | |
| Martin Caballero et al. | Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7–dependent tumors | |
| JP2015533376A5 (enExample) | ||
| Yu et al. | A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice | |
| Pishraft-Sabet et al. | Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96 | |
| RU2018123307A (ru) | Вакцинация с использованием альфа3 домена mica/b для лечения рака | |
| JP2010506926A5 (enExample) | ||
| JP2014139185A5 (enExample) | ||
| Öhlschläger et al. | The combination of TLR‐9 adjuvantation and electroporation‐mediated delivery enhances in vivo antitumor responses after vaccination with HPV‐16 E7 encoding DNA | |
| Shayeghpour et al. | Hepatitis C virus DNA vaccines: a systematic review | |
| Zhang et al. | Hepatitis B virus core antigen epitopes presented by HLA‐A2 single‐chain trimers induce functional epitope‐specific CD8+ T‐cell responses in HLA‐A2· 1/Kb transgenic mice | |
| Wang et al. | Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice | |
| Kraynyak et al. | Tapping the potential of DNA delivery with electroporation for cancer immunotherapy | |
| Kim et al. | Virus-like particles presenting flagellin exhibit unique adjuvant effects on eliciting T helper type 1 humoral and cellular immune responses to poor immunogenic influenza virus M2e protein vaccine | |
| CN110548136A (zh) | 汉坦病毒长肽疫苗 | |
| JP2009511452A (ja) | Ｃ型肝炎の予防および治療のための免疫刺激物質の組合せ | |
| Meseda et al. | Percutaneous vaccination as an effective method of delivery of MVA and MVA-vectored vaccines |